- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.01. | AstraZeneca to acquire China rights for AbelZeta's CAR-T therapy | ||
| 19.01. | FDA grants Novartis' ianalumab breakthrough therapy status for Sjögren's disease | ||
| 16.01. | FDA prevails over EMA in 2025 novel drug approvals | ||
| 16.01. | J&J's Caplyta doubles remission rate in MDD patients | ||
| 16.01. | UK's MHRA gives high-dose Wegovy the go-ahead in obesity | ||
| 16.01. | InterAx and Alveus collaborate on small-molecule metabolic treatment | ||
| 16.01. | Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal | ||
| 15.01. | JPM26: Fujifilm's modular manufacturing answer to pharma tariffs | ||
| 15.01. | JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success | ||
| 15.01. | Novo Nordisk Foundation pours $850m into European life sciences economy | ||
| 15.01. | JPM26: Jazz sells PRV for $200m, targets deals in 2026 | ||
| 15.01. | FDA and EMA release collaborative AI framework for drug development | ||
| 14.01. | JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries | ||
| 14.01. | JPM26: Bayer evades patent cliff in a way it may not be able to repeat | ||
| 14.01. | JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition | ||
| 14.01. | Drugmakers welcome FDA's GLP-1RA suicide warning removal request | ||
| 14.01. | JPM26: Tryngolza set to become first wholly owned Ionis blockbuster | ||
| 14.01. | JPM26: 2025 a "breakout year" for rare disease biotechs | ||
| 14.01. | JPM26: BioNTech gears up for multiproduct oncology status by 2030 | ||
| 14.01. | JPM26: Amgen touts MariTide's weight loss, T2D potential off Phase II data | ||
| 14.01. | BD invests $110m to expand US prefillable syringe production | ||
| 14.01. | Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease | ||
| 13.01. | JPM26: GSK banks on recent AI deals to offset patent expiries | ||
| 13.01. | JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery | ||
| 13.01. | JPM26: J&J leans on immunology launches to fuel annual growth |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.